Day Two
Tuesday 11th February 2025
8:30 am Check In, Coffee & Light Breakfast
9:25 am Chair’s Opening Remarks
CLINICAL UPDATES ON NOVEL MECHANISMS FOR SCHIZOPHRENIA, MUSCARININCS & BEYOND
9:30 am CLE-905, a potent M1/M4 entering First-in-Human: Similarities to Xanomeline & targeted differentiation from Cobenfy
Synopsis
- Target engagement pattern is similar to Xanomeline, confirmed by qEEG
- Dual M1/M4 agonist
10:00 am KCC2 Direct Activators to Modulate Neuronal Hyperexcitation in Psychosis
Synopsis
- Transforming the treatment landscape for neurological disorders
- Reviewing a novel target which offers a promising new therapeutic avenue for neuropsychiatric, neurodevelopmental and neurodegenerative disorders
10:30 am Morning Break & Refreshments
ADVANCING MORE TRANSLATABLE MODELS TO BETTER PREDICT ANTIPSYCHOTIC EFFICACY
12:00 pm Animal Models of Psychosis – How to Show Antipsychotic Efficacy of Novel Drugs Based on Non-Dopaminergic Mechanisms
Synopsis
- Enhancing understanding of muscarinic agonism in animal psychosis models
- Overcoming differences in muscarinic expression patterns and coupling of different receptors between animals and humans
12:30 pm Unmet Needs & Translational Aspects: Development of Next Generation Treatments for Psychiatric Indications
Synopsis
- Exploring target receptors and mechanisms of action across indications
- Assessing safety, tolerability, and compliance in psychiatric disorders
- Reviewing pharmacoeconomics in the psychosis landscape
1:00 pm Lunch & Networking Break
2:30 pm Enhancing Safety, Minimizing Side Effects, & Improving Patient Outcomes
Synopsis
- Understanding how non-specific mechanisms contribute to widespread off-target effects and exploring new approaches to minimize these risks
3:00 pm
BUILDING ON COBENFY TRIUMPH: WHAT DOES THIS MEAN FOR THE EVOLVING COMMERCIAL LANDSCAPE?
Synopsis
- Key hurdles in securing patents for psychotic medications and innovations
- Strategies for extending patent life (e.g., formulation changes, new indications)
- Cost factors unique to psychotic medication, including long trial durations and patient recruitment challenges
- Understanding the high-risk nature of psychiatric drug development and its impact on investor interest
- Key investment drivers and barriers to funding psychosis treatment research
- The role of public and private sectors in bridging funding gaps for mental health innovation